Uni-Bio Science Group (HK690) 联康生物科技集团

联康集团打造一流生物制剂车间 开展三合一CMO服务 有效利用资产价值拓充收入来源 共享生产力提升综合竞争力 联康生物科技集团有限公司（股份代号：690）之全资附属公司北京博康健基因科技有限公司（「北京博康健」）引进国际领先的无菌注射剂生产线-冻干粉针注射剂生产线和卡式瓶/预灌充注射器生产线，发展合同定制生产组织（「CMO」）服务，可满足无菌、高质量、高精度生物制品大批量生产需求。本集团认为，鉴于在中国生产预灌充注射制品的独特性，生产商需投入大量生产力及基础建设才能支持高质量生产，因此本集团新开展的CMO业务，将可为合作方节约相关成本，也可为本集团的非主营业务带来可观的利润率。本集团现阶段正在制定定价策略，让已投放的优质资产创造最高回报。

On August 28, 2024, Uni-Bio Science Group reported a 9.5% increase in revenue to HK$273.6 million for the first half of the year, with the gross profit margin rising to 84.3%. The Group advanced in osteoporosis, eye care, and medical aesthetics. Pinup®sales grew 12.8% year-on-year. The Group's significant product launch this year, Bogutai®, achieved HK$18.8 million in sales in just four months.Profits hit a record HK$67.4 million, up 71.0% year-on-year, due to effective strategies and operational efficiency. In January 2024, the NMPA accepted the application for the Diquafosol sodium eye drops, expected to launch in January 2025, marking a significant step forward in eye care. High-end skincare product Skbrella™ FN wil launch in the second half of 2024 to boost brand presence in dermatology. Partnering with Great Bay Bio and Tigermed's Pebble Accelerator in May 2024 to develop innovative weight loss treatments. Uni-Bio Science Group will keep expanding in various fields, sales channels, and strengthen production and R&D for the future. For more information, please follow the link to the full press release. https://lnkd.in/gHGRrc5w #2024MidYearReport #Milestone

Recently, Uni-Bio Science Group is pleased to announce a strategic cooperation with Chongqing Minji Medical Device Co., Ltd. In this partnership, Uni-Bio Science Group has secured the exclusive distribution rights nationwide for Chongqing Minji's flagship product – a hydrogel wound dressing designed for post-skin injury and minimally invasive surgery wound healing. And also attained the exclusive distribution rights for Chongqing Minji's soon-to-be-approved collagen liquid dressing. Most notably, both companies are expected to jointly launch the first batch of Skbrella medical devices in China in the future. Lastly, Uni-Bio Science has the option to further deepen its strategic alliance with Chongqing Minji by investing in and potentially acquiring the company within the next 24 months. This partnership expands the Group's business into the medical aesthetics device sector and enhances its long-term strategy in biopharmaceuticals and medical aesthetics. For more information, please follow the link to the full press release. https://lnkd.in/gHbhDnph #StrategicCooperation #MedicalAestheticDevices #Milestone

Uni-Bio Science Group is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”). During the Year, the Group achieved record-breaking revenue, witnessing a 10.1% year-on-year (“YoY”) increase to approximately HK$484.7 million. Sales of Pinup ® and GeneTime ® performed well, registered an increase of 15.0% YoY and 9.54% YoY respectively. Profit for the year experienced a remarkable 84.04% YoY surge, reaching approximately HK$70.9 million, attributed to the Group's diligent cost control measures.  The marketing application of the Group’ s Bogutai® (teriparatide injection) was approved by the China National Medical Products Administration (“NMPA”), marking a significant breakthrough for the Group in orthopedic disease treatment and providing patients with expanded options. The NMPA’s acceptance of the marketing application for Diquafosol Sodium eye drops on 23 January 2024 marks a pivotal step towards its anticipated market approval in the first quarter of 2025.  The Group has reached a significant milestone with the successful introduction of Skbrella™ FN and plans to officially launch a self-owned medical aesthetic brand utilizing Skbrella™ FN in 2024. For more information, please follow the link to the full press release. https://lnkd.in/gWx7hcDJ #annualreport2023 #milestone

A new chapter, Uni-Bio Science Group releases corporate video, at the time of the launch of Bogutai ®

Uni-Bio Science Group is pleased to announce the acceptance of its marketing application for Diquafosol Sodium eye drops by the China National Medical Products Administration (“NMPA”) on 23 January 2024, with the acceptance number “CYHS2400318“. This acceptance marks a pivotal step in expanding the Group’s ophthalmology drug repertoire and providing patients with more diverse treatment options upon successful marketing approval. Diquafosol Sodium eye drops complement the Group's robust ophthalmic drug portfolio, following GeneSoft®, which is expected to be approved for marketing in the first quarter of 2025. https://lnkd.in/gaNAABPN #DiquafosolSodium #Eyedrops #Milestone #Ophthalmology

Uni-Bio Science Group is excited to announce that the China National Medical Products Administration ("NMPA") has officially approved the marketing application for BOGUTAI® (teriparatide injection) on January 16, 2024, with the approval number "国药准字S20240004". This significant milestone heralds a transformative era in orthopedic disease management and expands the choices available to patients. It not only matches FORTEO in effectiveness but also surpasses it with a superior safety profile. Developed in a strategic partnership with Swiss self-care titan Ypsomed, BOGUTAI® boasts a pre-filled structure design featuring ultra-fine needles, ensuring high dosage accuracy. This design significantly alleviates patient discomfort, enhancing compliance. Uni-Bio is gearing up for the launch of BOGUTAI®, an endeavor that has been painstakingly prepared for over a year. The company has more than doubled its sales force and orchestrated comprehensive pre-marketing academic promotions directed at potential target customers. With BOGUTAI®’s market approval, the Group stands at the precipice of exponential growth, promising a future filled with innovative healthcare solutions and robust returns on investment. https://lnkd.in/gQyyicHG #PTH #TeriparatideInjection #Milestone #Osteoporosis